Results 111 to 120 of about 1,228 (155)

Molecular characterization of fluoroquinolone resistance in invasive clinical isolates of Streptococcus pneumoniae susceptible to delafloxacin. [PDF]

J Antimicrob Chemother
Cercenado E, Marín M, Iglesias M, Jiménez L, Pérez-Abeledo M, Sanz JC.   +5 more
europepmc   +1 more source

Biochemical discordance of a urinary fluoroquinolone-resistant <i>Escherichia coli</i> ST1193 as a <i>Shigella</i> species: A case report. [PDF]

IDCases
Peine B, Juan MRS, Choi H, Hwang M, Jinadatha C, Navarathna DH.   +5 more
europepmc   +1 more source

Drug-Drug Interactions in Recently Approved Antibacterials: A Mini Review. [PDF]

Eur J Drug Metab Pharmacokinet
Baccari I, Bergmann F, Zeitlinger M.
europepmc   +1 more source

Novel use of oral delafloxacin monotherapy in staphylococcal prosthetic valve endocarditis: A case report. [PDF]

Infect Med (Beijing)
Mastroianni A, Vangeli V, Guadagnino G, Chidichimo L, Berardelli L, Greco S.   +5 more
europepmc   +1 more source

A Randomized, Observer-Blinded, Active-Controlled, Phase IIIb Study to Compare IV/Oral Delafloxacin Fixed-Dose Monotherapy With Best Available Treatments in a Microbiologically Enriched Population With Surgical Site Infections: The DRESS Study. [PDF]

Open Forum Infect Dis
Belev N, Tein A, Mangialardi G, Nuti A, Marino Merlo G, Scartoni S, Bertolotti M, Lerro M, Margaritora S.   +8 more
europepmc   +1 more source

Highly fluorescent method for ultra-sensitive estimation of delafloxacin in human plasma: greenness assessment. [PDF]

BMC Chem
Salman BI.
europepmc   +1 more source

Correction: Molecular resistance mechanisms to newly approved antibiotics (2017-2025) in WHO priority pathogens. [PDF]

Front Microbiol
Frontiers Production Office.
europepmc   +1 more source

Temocillin: a therapeutic alternative in bone and joint infections due to third generation cephalosporin-resistant Enterobacterales? [PDF]

J Antimicrob Chemother
Piquart L, Goutelle S, Maillard M, Boisset S, Carricajo A, Tristan A, Ranc AG, Laurent F, Dupieux C.   +8 more
europepmc   +1 more source

An evaluation of antibiotic options for the treatment of biothreat pathogens. [PDF]

Front Antibiot
Meinig JM, Nelson M, Cote CK, Emmett SR, Harding SV.   +4 more
europepmc   +1 more source

Molecular Dynamics-Guided Repositioning of FDA-Approved Drugs for PD-L1 Inhibition with In Vitro Anticancer Potential. [PDF]

Int J Mol Sci
Jiang D, Yoou MS, Cho S, Choi Y.
europepmc   +1 more source